TRAF7 (TNF receptor-associated factor 7) is an E3 ubiquitin and SUMO-protein ligase with critical roles in innate immunity, inflammation, and apoptosis 1. It potentiates MAP3K3-mediated activation of transcriptional regulators JUN/AP1 and DDIT3, while negatively regulating RLR-mediated innate immunity by promoting Lys-48-linked ubiquitination of TBK1 to suppress antiviral responses 2. TRAF7 also promotes Lys-29-linked polyubiquitination of NEMO/IKBKG and RELA, targeting them to lysosomal degradation and reducing NF-κB transcriptional activity 3. Mechanistically, TRAF7 interacts with KLF4 to regulate cellular senescence and cell cycle arrest 4. Clinically, TRAF7 mutations represent a major meningioma driver, occurring in nearly 25% of non-NF2 meningiomas 5. These mutations typically co-occur with KLF4(K409Q) or AKT1(E17K) and characterize benign tumors with chr16 stability originating from the medial skull base 5. High TRAF7 expression correlates with glioma recurrence and poor overall survival, making it a potential therapeutic target 4. Additionally, inherited TRAF7 mutations cause congenital cardiac and craniofacial defects through disruption of TRAF7-IFT57 interactions and cilia degradation 6, reflecting shared developmental origins from neural crest tissue.